XML 41 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
Note 10 - Commitments and Contingencies
12 Months Ended
Dec. 31, 2016
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]
10.
Commitments and contingencies
 
Operating lease commitments
 
The Company has several operating leases, primarily for offices. Payments under operating leases are expensed on a straight-line basis over the periods of their respective leases, and the terms of the leases do not contain rent escalation, contingent rent, renewal, or purchase options.
 
Rental expenses incurred under the operating leases for the years ended
December
31,
2014,
2015
and
2016
amounted to
$12,
$33
and
$136,
respectively.
 
The following table summarizes the future minimum lease payments under the operating lease as of
December
31,
2016:
 
     
$
 
Year ending December 31, 2017    
155
 
Year ending December 31, 2018    
57
 
Total    
212
 
 
Royalty payment
 
As part of the consideration to the seller for acquiring the worldwide patent of Plinabulin excluding the PRC and Hong Kong, Wanchun Biotech was required to pay royalties on a quarterly basis equal to
20%
of gross proceeds from the sales of the product, commencing on the
first
commercial sale of such product for
ten
years.
 
On
February
2,
2015,
the Company, Wanchun Biotech and Fortis Advisors LLC, in its capacity as an agent of the former stakeholders of the seller of the patent of Plinabulin transferred to Wanchun Biotech, entered into an agreement to terminate such royalty payment arrangements. The termination agreement will be effective upon the consummation of the Company’s IPO in the United States. If the IPO is consummated within
three
years following the agreement date, the Company is required to issue and allot such number of ordinary shares representing
10%
of the Company’s fully-diluted equity capitalization immediately prior to the IPO to a single corporate entity designated by the seller in lieu of the royalty payment. In connection with the Company IPO on the NASDAQ Capital Market completed on
March
14,
2017
(Note
11),
the Company issued
2,112,963
ordinary shares to Nereus Trust, an entity designated by the seller, and the royalty payment arrangements were terminated.